Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Lu AF20513 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Lundbeck A/S
- 07 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 06 May 2019 Planned End Date changed from 1 Feb 2022 to 1 May 2019.
- 06 May 2019 Planned primary completion date changed from 1 Feb 2022 to 1 May 2019.